CXCL12 is a CXC chemokine that contains multiple alternative splicing forms in humans. CXCL12 is involved in a variety of physiological and pathological processes, including embryogenesis, hematopoiesis, angiogenesis, and inflammatory responses, as well as cardiovascular disease (CVD). Creative BioMart Biomarker is capable to provide our customers with superior CXCL12 detection service, various detection methods ensuring high sensitivity for detecting biomarkers in different samples with different concentrations.
The CXC chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF-1), is one of the 17 members of the CXC chemokine family. CXCL12 is an important factor in physiological and pathological processes including embryogenesis, hematopoiesis, angiogenesis and inflammatory responses as it activates or induces migration of hematopoietic progenitor and stem cells, endothelial cells and most leukocytes. Therefore, the activity of CXCL12 is strictly regulated at multiple levels. CXCL12 has six splice variants in humans, each having a specific tissue distribution and in vivo activity. Controlled splice variant transcription and mRNA stability determine the CXCL12 expression profile. CXCL12 interacts with its receptor CXC chemokine receptor 4 (CXCR4) and atypical chemokine receptor 3 (ACKR3) and binds to glycosaminoglycans (GAGs) in tissues and on the endothelium, function under pathological and pathological conditions. The CXCL12/CXCR4 axis plays an important role in progenitor cell migration. Mobilization of hematopoietic stem cells, progenitor cells such as endothelial progenitor cells (EPC) and smooth muscle progenitor cells (SPC), are associated with a variety of diseases such as atherosclerosis. Studies have shown that the CXCL12/CXCR4 axis has anti-atherosclerotic effects. In addition to its effect on progenitor cells to mediate beneficial effects on atherosclerosis, CXCL12/CXCR4 can also affect disease progression by affecting a variety of cells associated with atherosclerosis.
Figure 1. Signal transduction pathways activated by CXCL12. (Janssens, R. 2018)
Genome-wide studies have shown a clear association between CXCL12 and CVD. Previous studies have shown that high levels of CXCL12 are expressed in vascular cells of human atherosclerotic lesions, but not in normal blood vessels. Studies in various humans have shown that CXCL12 is a potential regulator of atherosclerosis. A study comparing the levels of plasma CXCL12 in healthy controls with angina patients revealed a decrease in CXCL12 levels in the patient group. Patients with unstable angina have lower levels of CXCL12 than patients with stable angina. Taken together, this study demonstrates that CXCL12 has anti-atherosclerotic properties. In another study, platelet CXCL12 expression was significantly increased in patients with stable angina compared with healthy controls, indicating that CXCL12 has stronger atherogenic and pro-thrombotic. Therefore, CXCL12 can be used as an early biomarker for CVD.
Plasma, serum levels of CXCL12, can be used as a predictor of cardiovascular disease.
Creative BioMart Biomarker strictly controls each specific experimental step in the CXCL12 detection procedure to ensure high sensitivity, high accuracy and repeatable CXCL12 detection.
Please feel free to contact us if you would like to know more about CXCL12 detection. At Creative BioMart Biomarker, we not only provide high-quality CXCL12 detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design the best solution according to your specific requirements.